These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 20053329

  • 1. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
    Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M.
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
    [Abstract] [Full Text] [Related]

  • 2. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.
    Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH, Jelliffe RW, Aulagner G.
    Bone Marrow Transplant; 2003 Oct; 32(8):777-84. PubMed ID: 14520421
    [Abstract] [Full Text] [Related]

  • 3. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
    Punnett A, Sung L, Price V, Das P, Diezi M, Doyle J, Dupuis LL.
    Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
    Barkholt L, Remberger M, Bodegård H, Ringdén O, Böttiger Y.
    Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
    [Abstract] [Full Text] [Related]

  • 5. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Mohty M, Bagattini S, Chabannon C, Faucher C, Bardou VJ, Bilger K, Vey N, Gaugler B, Stoppa AM, Coso D, Ladaique P, Olive D, Viens P, Blaise D.
    Exp Hematol; 2004 Nov; 32(11):1097-102. PubMed ID: 15539088
    [Abstract] [Full Text] [Related]

  • 6. [Analysis of risk factors for the development of acute graft-versus-host disease in 151 cases of allo-hematopoietic stem cell transplantation].
    Chen Y, Lu DP, Liu KY, Dong LJ, Ren HY, Huang XJ, Chen H, Liu DH, Jiang Q, Chen YH, Xu LP, Zhang YC, Lu J, Gao ZY.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):74-7. PubMed ID: 15921621
    [Abstract] [Full Text] [Related]

  • 7. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [Abstract] [Full Text] [Related]

  • 8. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
    Zhu KE, Hu JY, Zhang T, Chen J, Zhong J, Lu YH.
    Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
    [Abstract] [Full Text] [Related]

  • 9. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.
    Izumi N, Furukawa T, Sato N, Okazuka K, Tsukada N, Abe T, Yano T, Kurasaki T, Masuko M, Toba K, Takahashi M, Aizawa Y.
    Bone Marrow Transplant; 2007 Nov; 40(9):875-80. PubMed ID: 17724440
    [Abstract] [Full Text] [Related]

  • 10. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF.
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [Abstract] [Full Text] [Related]

  • 11. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
    Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
    [Abstract] [Full Text] [Related]

  • 12. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
    Sun J, Meng FY, Liu QF, Xu D, Xu B, Liu XL.
    Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
    [Abstract] [Full Text] [Related]

  • 13. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor.
    Kanda Y, Hyo R, Yamashita T, Fujimaki K, Oshima K, Onoda M, Mori T, Sakura T, Tanaka M, Sakai M, Taguchi J, Kurakawa M, Maruta A, Okamoto S, Sakamaki H, Kanto Study Group of Cell Therapy.
    Am J Hematol; 2006 Nov; 81(11):838-44. PubMed ID: 16888784
    [Abstract] [Full Text] [Related]

  • 14. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
    Teuffel O, Schrauder A, Sykora KW, Zimmermann M, Reiter A, Welte K, Schrappe M.
    Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976
    [Abstract] [Full Text] [Related]

  • 15. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [Abstract] [Full Text] [Related]

  • 16. [Exploration of acute graft versus host disease and its risk factors after allo-hematopoietic stem cell transplantation].
    Chen YH, Huang XJ, Guo NL, Ren HY, Zhang YC, Xu LP, Gao ZY, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):61-3. PubMed ID: 12697096
    [Abstract] [Full Text] [Related]

  • 17. Acute gastrointestinal graft-versus-host disease in pediatric patients: serum albumin on day 5 from initiation of therapy correlates with nonrelapse mortality and overall survival.
    Goussetis E, Paisiou A, Kitra V, Peristeri I, Vessalas G, Stefanaki K, Panayotou I, Giamaiou K, Kontou E, Kitzoni M, Dimopoulou MN, Karkelis S, Kafritsa Y, Rapsomaniki E, Papassotiriou I, Tsirigotis P, Roma E, Graphakos S.
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1058-66. PubMed ID: 21073975
    [Abstract] [Full Text] [Related]

  • 18. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P, Piñana JL, Valcárcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [Abstract] [Full Text] [Related]

  • 19. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
    Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M.
    Am J Hematol; 2008 Mar; 83(3):226-32. PubMed ID: 17918253
    [Abstract] [Full Text] [Related]

  • 20. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.
    Solomon SR, Nakamura R, Read EJ, Leitman SF, Carter C, Childs R, Dunbar CE, Young NS, Barrett AJ.
    Bone Marrow Transplant; 2003 May; 31(9):783-8. PubMed ID: 12732885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.